Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, immunological and genetic disorders.
Sevenless Therapeutics Ltd. has patented son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, parkinsonism, neurofibromatosis type 1, atopic dermatitis and cholestasis, among others.
Sevenless Therapeutics Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, Parkinson's disease and neurofibromatosis type 1.
KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with overall response rates ranging between 34% and 43%.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized son of sevenless homolog 1 (SOS1) and GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Scientists at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed pyridazinopyridone derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors. As such, they are reported to be useful for the treatment of cancer, gingival fibromatosis, cardiofaciocutaneous and Noonan syndromes.
SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome resistance and achieve durable responses.
Accutar Biotechnology Inc. has patented new substituted quinoline derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.
